Neurotech International (CHIA:NTI) - Stock Price, News & Analysis

NTI Stock Overview

Neurotech International Limited, together with its subsidiaries, engages in the research, design, development, and manufacture of medical devices and solutions in Australia.

About the company

NTI fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Risk Analysis

Earnings have declined by 10.5% per year over past 5 years

Does not have a meaningful market cap (A$92M)

Shareholders have been diluted in the past year

Does not have meaningful revenue (A$3M)

Neurotech International Limited Competitors

Micro-X

ASX:MX1

AU$51.9m

EMVision Medical Devices

ASX:EMV

AU$194.8m

Nova Eye Medical

ASX:EYE

AU$57.2m

Optiscan Imaging

ASX:OIL

AU$80.2m

Price History & Performance

Summary of all time highs, changes and price drops for Neurotech International
Historical stock prices
Current Share Price	AU$0.10
52 Week High	AU$0.13
52 Week Low	AU$0.032
Beta	1.79
1 Month Change	12.64%
3 Month Change	33.12%
1 Year Change	79.82%
3 Year Change	68.03%
5 Year Change	210.61%
Change since IPO	-58.16%

Recent updates

Shareholder Returns

	NTI	AU Medical Equipment	AU Market
7D	-2.4%	-1.7%	-3.1%
1Y	79.8%	14.3%	4.0%

Return vs Industry: NTI exceeded the Australian Medical Equipment industry which returned 14.3% over the past year.

Return vs Market: NTI exceeded the Australian Market which returned 4% over the past year.

Price Volatility

Is NTI's price volatile compared to industry and market?
NTI volatility
NTI Average Weekly Movement	11.2%
Medical Equipment Industry Average Movement	10.2%
Market Average Movement	8.9%
10% most volatile stocks in AU Market	17.4%
10% least volatile stocks in AU Market	3.5%

Stable Share Price: NTI's share price has been volatile over the past 3 months.

Volatility Over Time: NTI's weekly volatility (11%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
2016	n/a	Peter James Griffiths	www.neurotechinternational.com

Neurotech International Limited, together with its subsidiaries, engages in the research, design, development, and manufacture of medical devices and solutions in Australia. The company is focused on development and commercializing Mente platform, a platform technology to monitor and play role in home-based therapies. Its products includes Mente Autism for the diagnosis and treatment of autism.

Neurotech International Limited Fundamentals Summary

How do Neurotech International's earnings and revenue compare to its market cap?
NTI fundamental statistics
Market cap	AU$91.74m
Earnings (TTM)	-AU$4.98m
Revenue (TTM)	AU$3.20m

27.2x

P/S Ratio

-17.5x

P/E Ratio

Is NTI overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
NTI income statement (TTM)
Revenue	AU$3.20m
Cost of Revenue	AU$28.87k
Gross Profit	AU$3.18m
Other Expenses	AU$8.16m
Earnings	-AU$4.98m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-0.0054
Gross Margin	99.10%
Net Profit Margin	-155.47%
Debt/Equity Ratio	0%

How did NTI perform over the long term?

See historical performance and comparison

NTI Stock Overview

Rewards

Risk Analysis

Neurotech International Limited Competitors

ASX:MX1

AU$51.9m

ASX:EMV

AU$194.8m

ASX:EYE

AU$57.2m

ASX:OIL

AU$80.2m

Price History & Performance

Recent News & Updates

Neurotech International Limited has completed a Follow-on Equity Offering in the amount of AUD 10 million.

Neurotech International Limited has completed a Follow-on Equity Offering in the amount of AUD 10 million.

Neurotech International Limited to Report Q1, 2024 Results on Oct 27, 2023

Neurotech International Limited, Annual General Meeting, Nov 15, 2023

Full year 2023 earnings released: AU$0.01 loss per share (vs AU$0.005 loss in FY 2022)

New minor risk - Financial data availability

Recent updates

Neurotech International Limited has completed a Follow-on Equity Offering in the amount of AUD 10 million.

Neurotech International Limited has completed a Follow-on Equity Offering in the amount of AUD 10 million.

Neurotech International Limited to Report Q1, 2024 Results on Oct 27, 2023

Neurotech International Limited, Annual General Meeting, Nov 15, 2023

Full year 2023 earnings released: AU$0.01 loss per share (vs AU$0.005 loss in FY 2022)

New minor risk - Financial data availability

Neurotech International Limited to Report Q4, 2023 Results on Jul 26, 2023

First half 2023 earnings released: AU$0.48 loss per share (vs AU$0.003 loss in 1H 2022)

Neurotech International Limited Announces First Patient Treated in Phase I/II PANDAS/PANS Trial

Neurotech International Limited Announces Approval for Additional Phase I/II ASD Trial Extension

Neurotech International Limited Receives HREC Approval for Phase I/II PANDAS/PANS Clinical Trial

Neurotech International Limited to Report Q3, 2023 Results on Jan 30, 2023

Neurotech International Limited Announces Grant of FDA Pre-IND Meeting for NTI164 in ASD

Neurotech International Limited Announces Passing of Professor Allan Cripps AO, Non-Executive Director

Neurotech International Limited Announces Commencement of Patient Randomisation and First Patient Successfully Treats Under New Phase II/III NTIASD2 Clinical Trial for Children with Autism Spectrum Disorder

Less than half of directors are independent

Neurotech International Limited, Annual General Meeting, Nov 30, 2022

Neurotech International Limited, Annual General Meeting, Nov 23, 2022

Neurotech International Limited Reports Further Significant Clinical Improvement at 20 Weeks for Paediatric Autism Patients Treated with NTI164

Neurotech International Limited Announces New Phase I/II Clinical Trial in Children with PANDAS/PANS

Neurotech International Limited Provides Autism Spectrum Disorder Phase I/II Clinical Trial Update

Less than half of directors are independent

Neurotech International Limited Announces Transition of Alexandra Andrews from Chief Executive Officer to a New Position of Chief Operating Officer

Full year 2022 earnings released: AU$0.005 loss per share (vs AU$0.015 loss in FY 2021)

Neurotech International Limited Announces Currently Finalising a Pivotal Phase II/III Clinical Trial Design to be Conducted in Australia

Neurotech International ORDINARY FULLY PAID to Be Deleted from OTC Equity

Neurotech International Limited Announces Executive Changes

Neurotech International Limited Announces Results with NTI164 in Paediatric ASD

High number of new directors

Neurotech International Limited Announces Important Developments Relating to the Study Protocol Assessing NTI164 in Children with Autism Spectrum Disorder

High number of new directors

Neurotech International Limited Announces Successful Developments Relating to Safety and Tolerability of NTI164 and Key Behavioural Parameters That Impact Autism Spectrum Disorder Patients

Neurotech International Limited Appoints Alexandra Andrews as Chief Executive Officer, Effective 8 March 2022

Neurotech International Limited Announces Nti164 Clinical Program Update

Full year 2021 earnings released: AU$0.015 loss per share (vs AU$0.011 loss in FY 2020)

Neurotech International Limited Announces the Continuation of Its Pre-Clinical Program in Neuro-Inflammatory Disease Models In-Line with Research and Development Pathway

Neurotech International Limited Initiates Phase I/II Open Label Study into Autism

Neurotech International Limited has completed a Follow-on Equity Offering in the amount of AUD 2 million.

Neurotech International Limited Announces Strategic Cultivation Partnership with CannaPacific Limited

Neurotech International Limited Announces the Expansion of Its Exclusive License with Dolce Cann Global Pty Ltd

Neurotech International Limited Provides an Update on Clinical Study Program

Neurotech International Limited has completed a Follow-on Equity Offering in the amount of AUD 2.5 million.

Neurotech International Limited Announces Initiation of Clinical Product Formulation Studies

Neurotech International Limited Announces Transition of Peter Griffiths as CEO

Neurotech International Limited Commences Landmark in Vitro Trials of Unique Cannabis Strains

Full year earnings released - AU$0.011 loss per share

Shareholder Returns

Price Volatility

About the Company

Neurotech International Limited Fundamentals Summary

27.2x

-17.5x

Earnings & Revenue